Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion (NAPA-3)

Trial Profile

Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion (NAPA-3)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms NAPA-3
  • Sponsors Nuvelo
  • Most Recent Events

    • 01 Mar 2010 Primary endpoint results published in the Journal of Vascular Surgery
    • 14 Jan 2008 Status changed from in progress to discontinued.
    • 06 Aug 2007 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top